US Stock MarketDetailed Quotes
PLRX Pliant Therapeutics
- 14.720
- +0.200+1.38%
Trading Nov 4 15:46 ET
895.00MMarket Cap-4763P/E (TTM)
15.250High14.180Low363.59KVolume14.400Open14.520Pre Close5.39MTurnover0.78%Turnover RatioLossP/E (Static)60.80MShares19.62052wk High2.28P/B689.12MFloat Cap10.22052wk Low--Dividend TTM46.82MShs Float43.920Historical High--Div YieldTTM7.37%Amplitude3.965Historical Low14.816Avg Price1Lot Size
Pliant Therapeutics Key Stats
Quarterly+Annual
YOY
| (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | (Q3)Sep 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | -82.95%-45.3M | 0.02%-30.27M | -22.96%-116.36M | 19.65%-25.1M | -95.83%-36.22M | -1.49%-24.76M | -47.70%-30.28M | -25.43%-94.63M | -57.26%-31.24M | 17.82%-18.5M |
| Net income from continuing operations | -35.59%-55.85M | -25.05%-46.96M | -30.83%-161.34M | -17.25%-41.11M | -35.51%-41.49M | -39.42%-41.19M | -33.62%-37.55M | -26.79%-123.32M | -42.92%-35.06M | -13.20%-30.62M |
| Depreciation and amortization | 30.40%622K | 13.50%513K | 0.99%1.84M | 1.98%464K | -1.32%448K | 3.92%477K | -0.66%452K | 18.76%1.82M | 8.85%455K | 17.01%454K |
| Other non cash items | 83.41%1.15M | 11.82%681K | 28.63%2.39M | -6.86%557K | 3.65%597K | 42.50%627K | 149.59%609K | 11.32%1.86M | 653.70%598K | -28.62%576K |
| Change In working capital | -127.56%-1.71M | 251.31%4.73M | -70.33%1.25M | 109.30%609K | -134.95%-2.44M | 817.43%6.21M | -200.90%-3.13M | -39.03%4.22M | -2,107.67%-6.55M | 1,220.42%6.99M |
| -Change in receivables | --0 | --0 | 13,120.00%1.98M | --0 | -54.95%1.58M | 145.91%1.72M | -275.43%-1.31M | -99.79%15K | -29.12%-501K | 1,494.09%3.51M |
| -Change in prepaid assets | -157.76%-3.44M | 887.61%3.75M | -1,170.41%-3.74M | 94.76%-152K | -354.15%-1.77M | -249.11%-1.33M | -146.99%-476K | 87.03%-294K | -112.23%-2.9M | 222.03%698K |
| -Change in payables and accrued expense | -68.48%2.05M | 297.51%1.35M | -12.25%5.75M | 192.81%1.87M | -165.68%-1.95M | 54.93%6.51M | -148.51%-682K | 82.74%6.55M | -181.75%-2.02M | 73.07%2.96M |
| -Change in other current assets | ---- | ---- | --0 | -52.92%-367K | --367K | ---- | ---- | 187.14%201K | -153.33%-240K | ---- |
| -Change in other current liabilities | 58.53%-282K | 44.66%-363K | -21.66%-2.75M | 16.42%-743K | -7.05%-668K | -44.68%-680K | -138.55%-656K | -28.73%-2.26M | -6.34%-889K | -38.36%-624K |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | -82.95%-45.3M | 0.02%-30.27M | -22.96%-116.36M | 19.65%-25.1M | -95.83%-36.22M | -1.49%-24.76M | -47.70%-30.28M | -25.43%-94.63M | -57.26%-31.24M | 17.82%-18.5M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 146.57%10.7M | 134.18%59.55M | 15.44%-127.01M | 59.43%31.92M | 121.46%38.25M | -453.78%-22.98M | -11,478.71%-174.21M | -303.81%-150.2M | -22.34%20.02M | -655.30%-178.25M |
| Net PPE purchase and sale | -107.46%-1.25M | -815.34%-1.49M | 47.67%-921K | 63.25%-61K | 86.49%-94K | -137.40%-603K | 74.69%-163K | 9.88%-1.76M | 71.96%-166K | -45.00%-696K |
| Net investment purchase and sale | 153.42%11.95M | 135.07%61.04M | 15.06%-126.09M | 58.42%31.98M | 121.60%38.35M | -431.53%-22.38M | -8,102.07%-174.05M | -296.22%-148.44M | -23.46%20.19M | -644.98%-177.56M |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | 146.57%10.7M | 134.18%59.55M | 15.44%-127.01M | 59.43%31.92M | 121.46%38.25M | -453.78%-22.98M | -11,478.71%-174.21M | -303.81%-150.2M | -22.34%20.02M | -655.30%-178.25M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 324.84%684K | -92.03%21.79M | 20.96%274.41M | -22.89%219K | -99.68%699K | -98.46%161K | 178,744.44%273.33M | 8,877.21%226.85M | -44.96%284K | 48,073.05%216.3M |
| Net issuance payments of debt | --0 | --19.91M | --0 | --0 | --0 | --0 | --0 | --10M | --0 | --0 |
| Net common stock issuance | -35.84%2.56M | --0 | 26.52%275.25M | 321.82%232K | -99.64%774K | --4M | --270.25M | 7,190.92%217.56M | -89.83%55K | --217.51M |
| Proceeds from stock option exercised by employees | ---- | -48.68%1.88M | ---- | ---- | ---- | ---- | 7,078.43%3.66M | ---- | ---- | ---- |
| Net other financing activities | ---- | ---- | -19.80%-847K | -105.68%-13K | 89.45%-75K | -723.81%-173K | -187.25%-586K | -54.70%-707K | 1,016.00%229K | -181.03%-711K |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | 324.84%684K | -92.03%21.79M | 20.96%274.41M | -22.89%219K | -99.68%699K | -98.46%161K | 178,744.44%273.33M | 8,877.21%226.85M | -44.96%284K | 48,073.05%216.3M |
| Net cash flow | ||||||||||
| Beginning cash position | 12.93%115.78M | 92.12%64.72M | -34.80%33.68M | 29.28%57.68M | 119.19%54.95M | 215.03%102.53M | -34.80%33.69M | 1.54%51.67M | -1.36%44.62M | -28.76%25.07M |
| Current changes in cash | 28.72%-33.91M | -25.83%51.06M | 272.58%31.03M | 164.37%7.04M | -86.04%2.73M | -536.47%-47.58M | 460.05%68.84M | -2,396.42%-17.98M | -269.93%-10.93M | 94.71%19.55M |
| End cash Position | 48.98%81.87M | 12.93%115.78M | 92.13%64.72M | 92.13%64.72M | 29.28%57.68M | 119.19%54.95M | 215.03%102.53M | -34.80%33.68M | -34.80%33.68M | -1.36%44.62M |
| Free cash flow | -83.53%-46.55M | -4.35%-31.76M | -21.67%-117.28M | 19.88%-25.16M | -89.22%-36.32M | -2.89%-25.36M | -43.97%-30.44M | -24.54%-96.39M | -53.52%-31.41M | 16.51%-19.19M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | -- | -- | -- | -- | Unqualified Opinion | -- | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data